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Inborn errors of metabolisms (IEMs) are a complex and heterogeneous group of monogenic disorders. It exhibits clinical symptoms due to an error in a genetic code, resulting 
in a lowered or deficient activity of an enzyme in a single 
pathway of intermediary metabolism [1]. Delay in the diagnosis 
and treatment of these disorders leads to a variety of adverse 
outcomes such as moderate-to-severe neuropsychological 
dysfunction, mental retardation, and even death. Early and timely 
diagnosis and intervention of these disorders can modify the 
course of disease and, hence, significant morbidity or mortality. 
Each disorder is individually rare, but their cumulative incidence 
is relatively high, around 1 in 1500–1 in 5000 live births [2,3].
Newborn screening identifies apparently healthy infants 
with serious inherited disorders. For metabolic disorders, 
the National Neonatology Forum, India, recommends that 
newborn screening (NBS) for three disorders - congenital 
hypothyroidism (CH), congenital adrenal hyperplasia (CAH), 
and G6PD deficiency - should be done in all babies [4]. It can 
be done by enzymatic assay for enzyme deficiency. Tandem 
mass spectrometry (TMS) can be used for rapid identification 
and quantification of a large number of different analytes from 
a single sample. Most of the data suggest that the samples be 
taken between 2 and 7 days of age. In the case of screening 
for CH, the huge variations in the levels of thyroid-stimulating 
hormone (TSH) in the first 48 h after birth make it sensible to 
do a TSH screening only after 48–72 h of birth. Other variables 
such as prematurity, blood transfusion, and parenteral nutrition 
also influence the timing of newborn screening. Early screening 
enables results to be obtained by 2 weeks of age, and the baby 
could be started on specific therapy or special elimination diets 
before morbidity sets in. The cord blood sample cannot be used 
to screen for metabolic disorders, as for their manifestation some 
feeding is required. IEMs cannot be detected biochemically until 
at least 12 h after the baby has taken feeds.
Natural history and the prevalence of each metabolic disorder 
vary from country to country, region to region, and also in different 
ethnic groups. Therefore, the existing data and studies cannot be 
applied to whole India. Preventing these disorders will be more 
useful than trying to let these disabilities develop and then treat.
MATERIALS AND METHODS
This prospective study was conducted during the period of 2015–
2016, in a tertiary care neonatal unit at Kolkata, India. After 
getting the ethical committee approval, all the live born neonates 
who were born in the hospital, irrespective of their gestational age 
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and birth weight, were included in the study. We obtained consent 
from the respective parents. The babies who were not initiated 
feeding before 3 days and were on parenteral nutrition since birth 
were excluded from the study.
On the 3rd day of life, newborns were subjected to detailed birth 
history, thorough clinical examination, with special emphasis on 
family history and history of consanguinity, and also metabolic 
screening for CH, G6PD deficiency, phenylketonuria (PKU), 
CAH, galactosemia, and cystic fibrosis. Sample consisted of heel 
prick blood sample collected and air dried on blotting paper. The 
dried sample was sent for ELISA-based enzymatic assay and 
TMS. Cost of the above-mentioned metabolic screening test was 
Rs. 500 and hospital bores the cost of these investigations.
RESULTS
A total number of 1373 newborns were screened; of which, four 
infants were screened positive including one each for CH, G6PD 
deficiency, CAH, and PKU, respectively. However, confirmatory 
test for PKU came out to be negative, and therefore, the incidence 
came out to be 1:1373 for CH, CAH, and G6PD deficiency each.
The newborn screened positive for CH, which was confirmed 
(table 1) serum TSH and T4 levels and was immediately 
commenced on thyroxin replacement therapy of 10–15 mcg/kg/
day. Baby is on regular follow-up, diagnosed to have permanent 
CH, and is on thyroxin replacement therapy. There was no 
maternal history of any thyroid disorder. Similarly, the male 
baby screened positive for G6PD deficiency also presented with 
neonatal hyperbilirubinemia and was confirmed by the analysis 
of enzyme activity. Baby is under regular follow-up, and there has 
not been any further episode of hyperbilirubinemia.
One male baby screened positive for CAH was confirmed by 
serum 17-OH progesterone level and was started glucocorticoid 
replacement therapy. There was no episode of salt-wasting 
crisis, and the baby was referred to a higher center with pediatric 
endocrinology department for further evaluation, management, 
and counseling. All above-mentioned four cases had no prior 
positive family history while the history of consanguinity was 
present in baby with G6PD deficiency.
DISCUSSION
Newborn screening identifies apparently healthy infants with 
serious inherited disorders, generally metabolic in origin, that are 
usually correctable by dietary or drug interventions before they 
suffer significant morbidity or mortality. It is originated with the 
work of Robert Guthrie, “Guthrie test,” in the 1960s, for detecting 
the metabolic disorder, PKU, and used for years to justify 
screening programs. In expanded newborn screening, a single 
test allows for early detection and treatment of a large number of 
disorders, and it can potentially prevent serious consequences [5].
The ICMR initiated a program to screen neonates in five 
centres in India - Delhi, Mumbai, Chennai, Hyderabad, and 
Kolkata. The study lasted for 5 years from 2007 to 2012 where the 
overall numbers of newborns enrolled for screening were 103,849 
for CH and 103,712 for CAH. As compered to our study where 
the incidence of CH was 1:1373, the incidence of CH overall was 
1 in 1130 newborns, varying from 1 in 727 in Chennai to 1 in 
1528 in Mumbai. Similarly, as compared to the incidence of CAH 
which was 1:1373 in our study, the overall incidence of CAH was 
1 in 5762 newborns, varying from 1 in 2036 in Chennai to 1 in 
9983 in Mumbai. Apart from the incidence rates, the ICMR study 
also provides good information on the actual process of screening 
and how to set up such a program [6]. As per Shriram et al. [7], 
it was 1 in 2000 newborns in Chennai where 30,514 babies were 
involved in the study. It was observed that the incidence of CAH 
was higher in southern states.
In our study, the incidence of G6PD deficiency came out to be 
1 in 1373(0.07%), whereas it was 0.89% as per the study of Kaur 
et al. [8] and 2% as per Pao et al. [9]. Many countries such as 
the United States do not advocate G6PD deficiency screening in 
their NBS program. The reason is that the appearance of jaundice 
alerts one to obtain assay of G6PD enzymes, so a deficient person 
would be detected even if newborn screening was not done. It 
must be stated, however, that, in the presence of acute hemolysis 
due to the presence of some fresh red blood cells, the value of 
G6PD enzyme may appear to be falsely normal.
The incidence of CH appears increasing over the past 
20 years. Whether the increase is real or is it the result of changes 
in the racial/ethnic population or lowering of screening test cut-
offs, or it may be due to an increase in preterm births. There is 
also uncertainty concerning permanent versus transient CH 
during monitoring. We need studies in affected infants detected 
by abnormalities on a second screening test, to confirm whether 
or not these infants have transient or permanent hypothyroidism.
The World Health Organization “Wilson–Jungner” criteria are 
used to determine the disorders that need to be included in the 
NBS program. According to it, a disease which has the following 
Table 1: Babies screened and number of positive cases
Clinical condition screened Number of babies screened Number of cases positive for NBS Confirmatory test (positive/negative)
CH 1373 01 Positive
Galactosemia 1373 00 -
G6PD deficiency 1373 01 Positive
PKU 1373 01 Negative
CF 1373 00 -
CAH 1373 01 Positive
PKU: Phenylketonuria, CH: Congenital hypothyroidism, CF: Cystic fibrosis, CAH: Congenital adrenal hyperplasia
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properties should be screened: (1) An important health problem; 
(2) the natural history of the condition should be adequately 
understood; (3) it should be recognizable in the early stages; 
(4) there should be a suitable test or examination; (5) the test 
should be acceptable to the population; (6) intervals for repeating 
the test should be determined; (7) there should be an accepted 
treatment; (8) facilities for diagnosis and treatment should be 
available; (9) there should be an agreed policy concerning whom 
to treat as patients; and (10) the costs of case finding should be 
economically balanced against the benefits [10].
An NBS program is not just a panel of screening tests, and it 
also integrates five parts as follows: (1) Testing of newborn infants, 
(2) follow-up of an abnormal screening result, (3) diagnostic 
testing and confirmation by specialized laboratory testing, 
interpretation, and treatment, (4) lifelong disease management, 
and (5) the NBS system’s evaluation, which makes regular and 
timely communication between nurseries, screening laboratories, 
health authorities, pediatricians, and subspecialists [11].
TMS is a powerful technology used for rapid identification and 
quantification of a large number of different analytes from a single 
sample, by separating the ions based on their molecular mass-to-
charge ratio and measuring their intensities. The application of 
TMS to newborn screening currently involves measuring mainly 
two groups of analytes, amino acids and acylcarnitine species, 
for the detection of aminoacidopathies, organic acidurias, and 
fatty acid oxidation defects. Advantages of using TMS for NBS 
include the following: (a) The analysis can be performed on very 
small quantities of blood or other body fluids; (b) the analysis 
uses two mass spectrometers concurrently. The first is used 
to separate the components of the mixture, hence eliminating 
or minimizing prior chromatographic separation; (c) the time 
required for the analysis is minimal; and (d) the process can be 
automated, permitting analysis of around 600 samples per 24 h, 
with a very modest cost per sample [11].
Newborn screening, as a routine part of the care of most 
newborns, is expanding considerably throughout the world. Many 
countries screen all newborns for PKU and hypothyroidism, 
while in some of the more developed countries, the routine 
screening panels include 20 or more conditions [12]. As per the 
American College of Medical Genetics recommendations, 29 core 
conditions that are detectable by TMS are considered appropriate 
for newborn screening [11].
The expanded newborn screening using TMS for 30–40 
inherited IEMs can be offered to the “well to do” families and 
strong family history of metabolic disorders. The incidence 
of CAH is higher in the southern states than in the northern 
states. This is another strong argument for initiating NBS in 
India [11-14]. Based on our study, we will recommend NBS 
for CH, CAH, and G6PD deficiency, and for CH, it should be 
included the nationwide program.
Our study also had a limitation as this being a hospital-
based study and sample size being small; the incidence rate 
may not reflect what is in the community. At the hospital, the 
measurements were done by a single investigator which may not 
be the same at community level where multiple health workers 
are involved. In this study, we did not test the usefulness of these 
tests after 4th day of life.
CONCLUSION
To minimize morbidity, mortality, and disabilities associated with 
the inherited metabolic disorders, we suggest a national pilot 
study, to evaluate the establishment of the expanded NBS in this 
country. Based on current evidence, all hospitals in urban areas 
in India should initiate NBS for CH, CAH, and G6PD deficiency 
at nominal cost (Rs. 500 in our study). Facilities for confirmation 
of diagnosis follow-up and treatment should be established. For a 
nationwide program, screening for CH should be set up.
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